Adolescents and adults are affected differently by vaping and have different health concerns, according to Ilona Jaspers, PhD, director of toxicology and the deputy director of the Center for Environmental Medicine, Asthma, and Lung Biology at the Gillings School of Global Public Health at the University of North Carolina.
Adolescents and adults are affected differently by vaping and have different health concerns, according to Ilona Jaspers, PhD, director of toxicology and the deputy director of the Center for Environmental Medicine, Asthma, and Lung Biology at the Gillings School of Global Public Health at the University of North Carolina. She is also a professor of pediatrics, microbiology, and immunology.
Transcript:
How are adolescents impacted by vaping differently than adults, and why does this occur?
So, I think it is because the lungs are not fully developed in teenagers. And so, are there any developmental concerns that could unfold later in life? That's certainly one thing. One aspect that we are currently really interested in is that about 18 months ago, all research, even the vaping research, had a shift towards COVID-19. Everyone is doing COVID-19. Everyone in the respiratory field is doing something related to COVID-19. And 1 concern for us was that there are epidemiological studies indicating that those who vape e-cigarettes, either alone or together with conventional cigarettes, are more likely to get COVID-19 and may have, other disease outcomes. So, we're still actively investigating that.
But another aspect that's hitting us, potentially right now, is does vaping potentially affect the ability and longevity of COVID-19 vaccine antibodies? And that is obviously of importance to teenagers and young adults because probably, once they get the vaccine, they think it's basically back to 2019 and are behaving accordingly. But are their behaviors or their their use of e-cigarettes and vaping actually modify potentially their immunity, either acutely or long term? That is something that we're actively investigating now.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More